Trials / Completed
CompletedNCT01257971
Non-interventional Study (NIS) to Assess Reaching of Cholesterol Target Values in Patients Treated With HMG-CoA Reductase Inhibitors
Non-interventional Study to Assess Reaching of Cholesterol Target Values in Patients Treated With 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) Reductase Inhibitors in Croatia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,868 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-centre non-interventional study of patients who are treated with any HMGCoA reductase inhibitor available in Croatia (rosuvastatin, simvastatin, atorvastatin and fluvastatin) for at least 6 months. All HMG-CoA reductase inhibitors must be prescribed in accordance with SmPCs approved in Croatia. Data collection for each patient will take place at a single visit. The investigator will complete a Case Report Form with the patient's demographics, the presence of the factors for high cardiovascular risk, current treatment, cholesterol values as well as with further treatment decision.
Conditions
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2010-12-10
- Last updated
- 2012-03-20
Locations
27 sites across 1 country: Croatia
Source: ClinicalTrials.gov record NCT01257971. Inclusion in this directory is not an endorsement.